Related Experiment Videos
[Treatment of myeloma in the elderly]
Laurent Garderet1, Françoise Isnard, Norbert-Claude Gorin
1Hôpital Saint-Antoine, service d'hématologie et de thérapie cellulaire, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France. laurent.garderet@sat.aphp.fr
Abstract:
The treatment of elderly patients with multiple myeloma was based for the last forty years on the combination of alkeran plus prednisone. The survival was short. Three new molecules, thalidomide, bortezomib and revlimid are completely changing the way we treat myeloma as well as the prognosis. These new molecules are tested either alone or in combination. The addition of thalidomide to alkeran plus prednisone has increased overall survival of two years. For the first time, major therapeutic improvements are emerging giving rise to better prognosis.
Related Concept Videos
Drug Dosing: Geriatric Patients
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution